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Original Article

A Neutralizing Monoclonal Antibody
for Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group*

A BS T R AC T
BACKGROUND

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease
in viral load and the frequency of hospitalizations or emergency department visits
among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on
the effect of this antibody in patients who are hospitalized with Covid-19.
METHODS

In this platform trial of therapeutic agents, we randomly assigned hospitalized
patients who had Covid-19 without end-organ failure in a 1:1 ratio to receive either
LY-CoV555 or matching placebo. In addition, all the patients received high-quality
supportive care as background therapy, including the antiviral drug remdesivir and,
when indicated, supplemental oxygen and glucocorticoids. LY-CoV555 (at a dose of
7000 mg) or placebo was administered as a single intravenous infusion over a 1-hour
period. The primary outcome was a sustained recovery during a 90-day period, as
assessed in a time-to-event analysis. An interim futility assessment was performed
on the basis of a seven-category ordinal scale for pulmonary function on day 5.
RESULTS

On October 26, 2020, the data and safety monitoring board recommended stopping enrollment for futility after 314 patients (163 in the LY-CoV555 group and 151
in the placebo group) had undergone randomization and infusion. The median interval since the onset of symptoms was 7 days (interquartile range, 5 to 9). At day 5,
a total of 81 patients (50%) in the LY-CoV555 group and 81 (54%) in the placebo
group were in one of the two most favorable categories of the pulmonary outcome.
Across the seven categories, the odds ratio of being in a more favorable category
in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.56 to 1.29; P = 0.45). The percentage of patients with the primary safety
outcome (a composite of death, serious adverse events, or clinical grade 3 or 4
adverse events through day 5) was similar in the LY-CoV555 group and the placebo
group (19% and 14%, respectively; odds ratio, 1.56; 95% CI, 0.78 to 3.10; P = 0.20).
The rate ratio for a sustained recovery was 1.06 (95% CI, 0.77 to 1.47).
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CONCLUSIONS

Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ
failure. (Funded by Operation Warp Speed and others; TICO ClinicalTrials.gov number, NCT04501978.)
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he antiviral drug remdesivir has
been shown to decrease the time to recovery in hospitalized patients with coronavirus disease 2019 (Covid-19), and dexamethasone
has been shown to decrease mortality.1,2 However,
additional effective therapies are urgently needed. The use of passive immunity to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2)
to augment the humoral immune response to infection is a priority for clinical evaluation in patients with Covid-19.
Convalescent plasma, immune globulin, and
monoclonal antibodies are all being studied as
ways to boost the immune response to SARSCoV-2. One of these antibodies, LY-CoV555 (also
known as LY3819253 or bamlanivimab; AbCellera,
Eli Lilly, and the National Institute of Allergy and
Infectious Diseases) has been associated with a
decrease in viral load and the frequency of hospitalizations or emergency department visits in outpatients with Covid-19.3
To understand the possible role of neutralizing
monoclonal antibodies and other antiviral interventions in patients who are hospitalized with
Covid-19, the National Institutes of Health established the ACTIV-3/TICO (Therapeutics for Inpatients with Covid-19) platform4 for the efficient
conduct of trials. The first trial within the TICO
platform was a comparison of LY-CoV5555 and
placebo. We report here the preliminary results of
this trial.

Me thods
Trial Design and Treatments

The TICO platform protocol (available with the
full text of this article at NEJM.org) governs the
testing of multiple candidate therapies in a multigroup, multistage, double-blind design that allows for the efficient assessment of a range of
potential agents with the use of a pooled placebo
group when multiple therapies are being tested
concurrently.6 In order to respond to pandemic
dynamics, this platform protocol incorporates
an early futility and safety evaluation after the enrollment of 300 patients (stage 1). Stage 1 is then
followed by enrollment to the full sample size
(stage 2) for agents that pass the initial futility
and safety assessment.
LY-CoV555 was derived from the serum of a
Covid-19 survivor. LY-CoV555 binds with high affinity to an epitope within the receptor-binding
2
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domain overlapping the binding of the SARS-CoV-2
spike protein by angiotensin-converting enzyme
2. In preclinical models of Covid-19, the use of
LY-CoV555 improved clinical outcomes.5 A dose
of 7000 mg was chosen on the basis of pharmacokinetic and preliminary safety data.
Hospitalized patients with Covid-19 were randomly assigned in a 1:1 ratio to receive either
LY-CoV555 or matching placebo. In addition, all
the patients received high-quality supportive care
as background therapy, including remdesivir and,
when indicated, supplemental oxygen and glucocorticoids. Randomization was stratified according to the trial pharmacy, since each pharmacy
could serve more than one trial site. LY-CoV555
or placebo was administered as a single intravenous infusion over a 1-hour period. The infusion
was prepared by trial pharmacists. All other personnel, including investigators and research staff,
clinical staff, and patients, were unaware of the
trial-group assignments.
Other medications were permitted except
therapies that may provide exogenous antibodies
against SARS-CoV-2. Concurrent enrollment in
other randomized trials was not permitted for
the first 5 days after randomization.
Patients

We enrolled adult hospitalized patients who had
documented SARS-CoV-2 infection and a duration of symptoms attributable to Covid-19 of 12
days or less. Excluded from the trial were patients who had received SARS-CoV-2 intravenous
immune globulin, convalescent plasma from a
patient who had recovered from Covid-19, or another neutralizing monoclonal antibody against
SARS-CoV-2. During stage 1, patients were excluded from the trial if they had end-organ failure (including vasopressor therapy, new renalreplacement therapy, or the receipt of invasive
mechanical ventilation, extracorporeal membrane
oxygenation, or mechanical circulatory support)
or certain extrapulmonary complications. For
treatments that passed the early futility assessment, subsequent patients would be enrolled
according to expanded eligibility criteria, which
permit the presence of end-organ failure and extrapulmonary complications. Additional details
regarding the eligibility criteria are provided in the
Supplementary Appendix, available at NEJM.org.
The protocol was approved by a central institutional review board or ethics committee at each
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participating site, and written informed consent of death, serious adverse events, or grade 3 or 4
was obtained from all the patients or their le- adverse events through day 5.8 Details regarding
gally authorized representative.
the collection of adverse-event data are provided
in the Supplementary Appendix.
Primary and Secondary Outcomes

The TICO master protocol stipulates an overall
primary outcome (a sustained recovery, as assessed
in a time-to-event analysis, through day 90), as
well as two ordinal outcomes that are measured
at day 5 to direct the early futility assessment.
Given the pandemic dynamics, this design allows
for a rapid determination with respect to which
treatments will be advanced to a complete assessment. The two day 5 outcomes, which are both
classified according to seven-level ordinal scales,
are termed pulmonary and pulmonary-plus outcomes. The pulmonary outcome is based largely
on oxygen requirements, ranging from an ability
to perform all normal daily activities to death.
The pulmonary-plus outcome captures the range
of organ dysfunction that may be associated
with progression of Covid-19, such as respiratory
dysfunction and coagulation-related complications. Details regarding these outcomes as measured on ordinal scales, which were derived from
the scales recommended by the World Health
Organization7 and used in the Adaptive Covid-19
Treatment Trial 1 (ACTT-1),1 are provided in the
Supplementary Appendix.
Both ordinal outcomes were assessed on days
1 through 7, whereas the pulmonary outcome was
also ascertained on days 8 through 14 and on
day 28. The choice of day 5 as the primary day for
the evaluation was based on an evaluation of data
from ACTT-1,1 which showed that remdesivir was
associated with a better outcome than placebo
on day 5 on an ordinal scale similar to the one
used in our pulmonary outcome among patients
with characteristics that were similar to those of
the patients who were targeted in stage 1 of our
trial.
The primary efficacy outcome for treatments
that are being studied in TICO is the time to a
sustained recovery, which was defined as hospital
discharge to home and remaining at home for at
least 14 days. A key secondary outcome was death
from any cause. Deaths and serious adverse
events were assessed during 90 days of follow-up.
Data regarding clinical organ failure, serious infections, and clinical adverse events of grade 3 or
4 were collected through day 28.
The primary safety outcome was a composite

Statistical Analysis

We determined that the enrollment of 300 patients in stage 1 would provide a power of 95% to
detect an odds ratio of 1.60 for a more favorable
day 5 outcome on the two ordinal scales for
LY-CoV555 over placebo, using a one-sided test
with a type I error of 0.30. For treatments that
advance to stage 2, the planned sample size was
1000 patients (300 enrolled during stage 1 and
700 enrolled during stage 2) with 90 days of
follow-up. Additional details regarding the calculations for the stage 1 sample size and total
sample size are provided in the Supplementary
Appendix. Unless otherwise stated, the analysis
cohort for this preliminary report is the modified intention-to-treat population, which includes
all the patients who received all or part of the
LY-CoV555 or placebo infusion (Fig. S1 in the
Supplementary Appendix).
An independent data and safety monitoring
board reviewed interim data and used prespecified guidelines to assess futility on the basis of
treatment comparisons of the two ordinal outcomes on day 5. These and other guidelines that
were provided to the data and safety monitoring
board are listed in the protocol and in the Supplementary Appendix.
Follow-up data for all analyses were administratively censored on October 26, 2020, the date
on which all trial sites were informed of the recommendations of the data and safety monitoring
board to stop the trial for futility. The analysis
data set was locked on November 6, 2020, and
includes deaths, serious adverse events, organfailure events, and hospital discharges that occurred up to October 26.
To estimate the treatment effect on the ordinal pulmonary and pulmonary-plus outcomes on
day 5, we estimated the summary odds ratio of a
better outcome with LY-CoV555 than with placebo
using proportional-odds models9 that included
the treatment-group indicator. The primary efficacy analysis was adjusted for the ordinal pulmonary category at the time of trial entry and
the trial pharmacy; 95% confidence intervals and
P values were calculated. P values are two-sided,
unless otherwise noted.
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We used logistic regression to perform the primary safety analysis, which compared LY-CoV555
with placebo with respect to the percentage of
patients who had died or had serious adverse
events or new grade 3 or 4 adverse events by
day 5 after adjustment for the trial pharmacy.
The methods that were used for summarizing
time-to-event outcomes, other outcomes, and subgroups are described in the Supplementary Appendix, along with a post hoc analysis of adjusted
and unadjusted summary statistics, including
adjustments for a chance imbalance in risk factors for severe Covid-19 with the use of a risk score.
Statistical analyses were performed with the use
of SAS software, version 9.4 (SAS Institute) and
R software, version 4.0.10

R e sult s
Patients

From August 5 to October 13, 2020, a total of
326 patients were enrolled at 31 trial sites, including 23 in the United States, 7 in Denmark,
and 1 in Singapore. The analysis population was
restricted to the 314 patients who received an
infusion of LY-CoV555 (163 patients) or placebo
(151 patients); of the 12 patients who did not receive an infusion, 8 had undergone randomization on the day that the data and safety monitoring board recommended stopping enrollment
(Fig. S1). Characteristics of the patients are provided in Table 1. Several baseline characteristics
indicated that by chance more patients in the
LY-CoV555 group than in the placebo group may
have been at greater risk for disease progression.
A total of 298 patients (95%) had begun to
receive remdesivir before or on the day of randomization; 40% had already started receiving it
at the time of randomization. In addition, 49%
were receiving glucocorticoids, and 51% were
receiving heparinoids at baseline (Table 1 and
Table S1). Concomitant treatments that had been
prescribed on day 5 are summarized in Table S2.
Data were available with respect to the day 5
outcomes in all but 3 patients (99%). The median
duration of follow-up was 31 days. At the time of
this report, 279 patients (89%) had been discharged from the hospital.
Efficacy Outcomes

The distribution of patients across the seven categories of the pulmonary ordinal outcome on
4
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day 5 were similar in the LY-CoV555 group and
the placebo group (Fig. 1A). A total of 81 patients (50%) in the LY-CoV55 group were in one
of the two most favorable categories, as compared with 81 patients (54%) in the placebo
group; 90 patients (55%) and 85 patients (56%),
respectively, had been discharged from the hospital by day 5. The odds ratio of being in a more
favorable category in the LY-CoV555 group than
in the placebo group was 0.85 (95% confidence
interval [95% CI], 0.56 to 1.29; P = 0.45) (Fig. 1A
and Table 2). The pulmonary and pulmonaryplus outcomes were almost identical; only 2 patients (both in the placebo group) were in a
worse category of the pulmonary-plus outcome
than their pulmonary category (1 owing to vasopressor use and 1 owing to stroke). The between-group comparison showed similar results
for the pulmonary-plus outcome (odds ratio, 0.87;
95% CI, 0.57 to 1.31; P = 0.50) (Table 2). Results
for both outcomes met the prespecified criteria
for futility.
The proportional-odds assumption was met
for both models. The primary findings were
unaffected by further adjustment with the use of
a risk score that considered potential baseline
risk factors for the pulmonary outcome on day 5
(Table S3). The odds ratios for both ordinal outcomes were less than 1.0 for all assessed time
points, including days 1 through 7, day 14, and
day 28 (Table S4).
Among 167 patients who were followed for at
least 28 days or who died within this time
frame, 71 of 87 patients (82%) in the LY-CoV555
group and 64 of 81 patients (79%) in the placebo
group had a sustained recovery (rate ratio, 1.06;
95% CI, 0.77 to 1.47). In the overall cohort of
314 patients, hospital discharge occurred in 143
of 163 patients (88%) in the LY-CoV555 group
and in 136 of 151 patients (90%) in the placebo
group (rate ratio, 0.97; 95% CI, 0.78 to 1.20)
(Table 2, Fig. 1B and 1C, and Table S3).
Tables S5A and S5B summarize the association of the day 5 pulmonary ordinal outcome
with the time until a sustained recovery. The
median time until a sustained recovery was longer for worse categories of the pulmonary outcome on day 5. As compared with the best category of the pulmonary outcome (category 1:
ability to perform usual activities with minimal
or no symptoms), the rate ratio for a sustained
recovery was significantly below 1 for patients in
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Table 1. Characteristics of the Patients at Randomization.*
Characteristic

LY-CoV555
(N = 163)

Placebo
(N = 151)

Total
(N = 314)

Median age (IQR) — yr

63 (50–72)

59 (48–71)

61 (49–71)

Female sex — no. (%)

66 (40)

71 (47)

137 (44)

1 (1)

2 (1)

3 (1)

Current pregnancy — no. (%)
Race or ethnic group — no. (%)†
White

76 (47)

71 (47)

147 (47)

Hispanic

41 (25)

33 (22)

74 (24)

Black

33 (20)

34 (23)

67 (21)

Other

13 (8)

13 (9)

26 (8)

≥30

81 (50)

83 (55)

164 (52)

≥40

20 (12)

22 (15)

42 (13)

117 (72)

98 (65)

215 (68)

Hypertension requiring medication

82 (50)

72 (48)

154 (49)

Diabetes requiring medication

54 (33)

36 (24)

90 (29)

Renal impairment

24 (15)

9 (6)

33 (11)

Asthma

14 (9)

14 (9)

28 (9)

Body-mass index — no. (%)‡

Coexisting illness — no. (%)
Any

Heart failure

12 (7)

1 (1)

13 (4)

7 (5–9)

8 (5–9)

7 (5–9)

Remdesivir

60 (37)

66 (44)

126 (40)

Antibacterial agent

54 (33)

36 (24)

90 (29)

Glucocorticoid

80 (49)

74 (49)

154 (49)

106 (65)

95 (63)

201 (64)

ACE inhibitor or ARB

41 (25)

31 (21)

72 (23)

NSAID

17 (10)

16 (11)

33 (11)

None

44 (27)

42 (28)

86 (27)

<4 liters/min

60 (37)

57 (38)

117 (37)

≥4 liters/min

29 (18)

34 (23)

63 (20)

30 (18)

18 (12)

48 (15)

0

0

0

94 (47–156)

90 (45–139)

92 (47–151)

784 (560–1056)

810 (550–1310)

799 (552–1116)

Median no. of days since symptom onset (IQR)
Medication — no. (%)

Antiplatelet or anticoagulant agent§

Oxygen requirement — no. (%)
Supplementary oxygen

Noninvasive ventilation or high-flow device
Invasive ventilation or ECMO
Laboratory measures
Median C-reactive protein (IQR) — mg/liter
Median B-lymphocyte count (IQR) —

cells/mm3

*	Percentages may not total 100 because of rounding. ACE denotes angiotensin-converting enzyme, ARB angiotensinreceptor blocker, ECMO extracorporeal membrane oxygenation, IQR interquartile range, and NSAID nonsteroidal antiinflammatory drug.
†	Race or ethnic group was reported by the patients.
‡	The body-mass index is the weight in kilograms divided by the square of the height in meters.
§	Details regarding the types of antiplatelet and anticoagulation medications that were used are provided in Table S1 in
the Supplementary Appendix.
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each of the other categories, with a clear trend and the placebo group (16% and 14%, respectively)
toward a longer sustained recovery time in pa- (Table S6). Most of the organ-dysfunction events
tients with more severe illness.
were due to respiratory dysfunction (in 10% and
11%, respectively), whereas other rarer events
Organ Dysfunction and Serious Infection
(i.e., seen in <4%) were thromboembolic events,
The percentages of patients in whom organ dys- acute delirium, and hypotension leading to vasofunction or serious infection developed during pressor treatment. Intercurrent serious coinfecfollow-up were similar in the LY-CoV555 group tion was seen in only 3% of the cohort.
A Pulmonary Ordinal Outcome on Day 5
LY-CoV555

Category
Can independently undertake usual activities with
minimal or no symptoms
No supplemental oxygen; symptomatic and unable
to independently undertake usual activities
Supplemental oxygen <4 liters/min
Supplemental oxygen ≥4 liters/min or end-organ
manifestations
Noninvasive ventilation, high-flow oxygen, or severe
stroke (NIHSS score, >14)
Invasive ventilation, ECMO, mechanical circulatory
support, renal-replacement therapy, or vasopressor
Death

100
33 (22.0)

2

50 (31.1)

48 (32.0)

3

29 (18.0)

31 (20.7)

4

17 (10.6)

11 (7.3)

5

25 (15.5)

22 (14.7)

6

8 (5.0)

5 (3.3)

7

1 (0.6)

0 (0.0)

80

60

40

20

0

eb

55

ac
Pl

oV
LY

-C

Summary Odds Ratio
0.85 (95% CI, 0.56–1.29)
P=0.45

o

31 (19.3)

5

1

Cumulative Percentage

Better

Category

Worse

Placebo

no. of patients (%)

C Time to Hospital Discharge

100

100

80

80

60
40
LY-CoV555
Placebo

20

Cumulative Incidence (%)

Cumulative Incidence (%)

B Time to Sustained Recovery

60
40

Recovery Rate Ratio
1.06 (95% CI, 0.77–1.47)

0
0

10

20

30

LY-CoV555
Placebo

20

Discharge Rate Ratio
0.97 (95% CI, 0.78–1.20)

0
0

40

20

30

40

No. at Risk

No. at Risk
LY-CoV555
Placebo

10

Days from Randomization

Days from Randomization
87
81

86
81

41
41

9
10

3
4

LY-CoV555
Placebo

163
151

38
36

17
13

6
6

3
4

Figure 1. Pulmonary Ordinal Outcome at Day 5 and Time until Sustained Recovery and Hospital Discharge.
Panel A shows the pulmonary ordinal outcome at day 5 in the LY-CoV555 group and the placebo group. The summary odds ratio was estimated with the use of a proportional-odds model after adjustment for the baseline pulmonary category and trial pharmacy. In Panels B
and C, the cumulative time until a sustained recovery and hospital discharge, respectively, are Aalen–Johansen estimates; rate ratios
were calculated with the use of Fine–Gray models, stratified according to trial pharmacy. The rate ratios estimate the subdistribution
hazard ratios after accounting for the competing risk of death. ECMO denotes extracorporeal membrane oxygenation, and NIHSS National Institutes of Health Stroke Scale.
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Safety Outcomes

Overall, 99% of the patients completed the infusion of LY-CoV555; the infusion was paused temporarily in 3%. Most of the signs or symptoms
that were associated with the infusion were of
grade 1 or 2 in severity (Table 2 and Table S7).
Through day 5, the primary safety outcome (a

composite of death, serious adverse events, or
incident grade 3 or 4 adverse events) occurred in
31 of 163 patients (19%) in the LY-CoV555 group
and in 21 of 151 patients (14%) in the placebo
group (odds ratio, 1.56; 95% CI, 0.78 to 3.10)
(Table 2 and Table S8). Through day 28, with the
inclusion of organ dysfunction and serious in-

Table 2. Summary of Major Outcomes.*
Outcome
Efficacy outcomes‡
Pulmonary ordinal outcome at day 5 — no./total no. (%)
Category 1: best
Category 2
Category 3
Category 4
Category 5
Category 6
Category 7: worst
Pulmonary-plus ordinal outcome at day 5 — no./total no. (%)
Category 1: best
Category 2
Category 3
Category 4
Category 5
Category 6
Category 7: worst
Sustained recovery through Oct. 26 — no./total no. (%)
Discharge from hospital through Oct. 26 — no. (%)
Safety outcomes‖
Infusion reaction — no. (%)**
Composite safety outcome — no. (%)‡‡
Through day 5
Through day 28
Composite safety outcome, organ dysfunction, or serious
coinfection through day 28 — no. (%)
Death through Oct. 26 — no. (%)

LY-CoV555
(N = 163)

Placebo
(N = 151)

Comparison
(95% CI)†

P Value

31/161 (19)
50/161 (31)
29/161 (18)
17/161 (11)
25/161 (16)
8/161 (5)
1/161 (1)

33/150 (22)
48/150 (32)
31/150 (21)
11/150 (7)
22/150 (15)
5/150 (3)
0

0.85 (0.56–1.29)§

0.45

31/161 (19)
50/161 (31)
29/161 (18)
17/161 (11)
25/161 (16)
8/161 (5)
1/161 (1)
71/87 (82)
143 (88)

33/150 (22)
47/150 (31)
31/150 (21)
12/150 (8)
21/150 (14)
6/150 (4)
0
64/81 (79)
136 (90)

0.87 (0.57–1.31)§

0.50

1.06 (0.77–1.47)¶
0.97 (0.78–1.20)¶

NA
NA

23 (14)

14 (9)

1.64 (0.79–3.44)††

0.19

31 (19)
38 (23)
49 (30)

21 (14)
30 (20)
37 (25)

1.56 (0.78–3.10)††
1.22 (0.75–1.98)§§
1.25 (0.81–1.93)§§

0.20
0.42
0.31

9 (6)

5 (3)

2.00 (0.67–5.99)§§

0.22

*	NA denotes not applicable.
†	The difference between the LY-CoV555 group and the placebo group was calculated as an odds ratio, rate ratio, or hazard ratio, as indicated in the table.
‡	The pulmonary and pulmonary-plus outcomes were calculated with the use of a seven-level ordinal scale, ranging from an ability to do
usual activities with minimal or no symptoms (category 1) to death (category 7). The pulmonary outcome is based largely on oxygen
requirements, and the pulmonary-plus outcome also captures the range of organ dysfunction that may be associated with progression of
Covid-19, such as respiratory dysfunction and coagulation-related complications. Estimates for efficacy outcomes that are greater than 1.0
favor LY-CoV555 over placebo.
§	This odds ratio was estimated from a proportional-odds model that was adjusted for baseline ordinal category and trial pharmacy.
¶	This rate ratio was estimated from a Fine–Gray model to account for the competing risk of death, stratified according to trial pharmacy.
‖	Estimates for safety outcomes that are greater than 1.0 favor placebo over LY-CoV555.
**	Types of infusion reactions are provided in Table S7 in the Supplementary Appendix.
††	This odds ratio was estimated from a logistic-regression model that was adjusted for the trial pharmacy.
‡‡	The composite safety outcome was defined as death, a serious adverse event, or an adverse event of grade 3 or 4. Additional details are
provided in Tables S8 and S9.
§§	This hazard ratio was estimated from a proportional-hazards regression model stratified according to trial pharmacy.
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fection along with the composite safety outcome, the hazard ratio was 1.25 (95% CI, 0.81 to
1.93). Most events in the composite safety outcome were grade 3 or 4 adverse events (Table 2
and Fig. S2C).
During 28 days of follow-up, a primary safety
event occurred in 38 of 163 patients (23%) in the
LY-CoV555 group and in 30 of 151 patients
(20%) in the placebo group (Table 2, Table S9,
and Fig S2A). Most of the events were classified
as respiratory, thoracic, mediastinal, general, or
psychiatric, according to the criteria of the
Medical Dictionary for Regulatory Activities, version
23.1 (Table S10).
A total of 14 participants died, 9 in the
LY-CoV555 group and 5 in the placebo group
(hazard ratio, 2.00; 95% CI, 0.67 to 5.99). Of the
14 deaths, 12 were attributed to worsening of
Covid-19 and 2 to cardiopulmonary arrest (Table 2 and Fig. S2B).
Except for a slight decrease in the mean serum creatinine level from baseline to day 5 in the
LY-CoV555 group as compared with no change in
the placebo group, no significant between-group
differences were seen with respect to intrapatient
changes in key laboratory values (Table S11).
Subgroup Analyses

Patients who entered the trial in a worse category on the pulmonary ordinal scale tended to be in
a worse category on day 5 (Fig. S3 and Tables S12
and S13). No evidence for a differential treatment
effect across baseline categories was seen (P = 0.78
for interaction). The distributions across the
seven categories of the pulmonary outcome on
day 5 were similar in the two groups within each
baseline category. LY-CoV555 showed no evidence
of benefit in any of the baseline categories. No
significant interaction was observed for the effect
size of either ordinal outcome at day 5 with respect to several other prespecified subgroups that
were defined according to baseline status, including categories of symptom duration (≤5 days, 6 to
8 days, and ≥9 days) (Table S13).

Discussion
In this preliminary report of the results of the
first TICO trial, we found that hospitalized patients with Covid-19 who received a single infusion of the neutralizing monoclonal antibody
LY-CoV555 (at a dose of 7000 mg) did not have
8

of

m e dic i n e

better clinical outcomes at day 5 than those who
received placebo. Most of the patients (95%)
were also receiving remdesivir. Thus, LY-CoV555
met the prespecified criteria for futility and further enrollment was stopped. The day 5 outcomes
that were used for an early assessment of futility
were closely associated with the primary outcome
of the time until a sustained recovery, which was
no better in the LY-CoV555 group than in the placebo group. Taken together, these results indicate
a low likelihood that LY-CoV555 improves outcomes among hospitalized patients with Covid-19.
The sample size of more than 300 patients for
the early futility assessment provided high statistical power for determining whether recruitment should continue to the full sample size of
1000 patients. The selection of the day 5 timing
for determining early efficacy and futility was
based on results from other trials, including the
ACTT-1 evaluation of remdesivir as compared
with placebo.1 As in ACTT-1, similar results in
the two groups were observed at all time points
evaluated in our trial.
We observe that, in general, patients underwent randomization at a point in the disease
course before the development of organ failure.
The enrollment of such patients before the early
futility assessment was by design, under the assumption that the greatest effect of an antiviral
agent would be observed in patients with less
severe illness. Reasons for the lack of benefit for
LY-CoV555 in this trial are unknown and may
include slow or ineffective penetration of the
antibody into infected tissue, minimal intrinsic
potency, rapid selection of escape mutants no
longer neutralized by the agent,11,12 and harmful
effects of the antibody. It has been hypothesized
that such harmful effects (which have been described as “antibody-dependent enhancement”)
could theoretically be associated with increased
viral replication or exaggerated inflammation.13,14
Additional research will be required to clarify
whether antibody-dependent enhancement will
be observed in patients with Covid-19.
Although the trial was not adequately powered for robust subgroup analyses, we identified
no evidence that the effect of LY-CoV555 on the
ordinal outcomes at day 5 differed according to
any subgroup, including the baseline pulmonary
ordinal category and the duration of symptoms
before enrollment. Assessments of serologic status and viral load in the patients at baseline are
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ongoing. Despite chance imbalances in illness
severity at baseline, adjusted analyses did not
suggest benefit for LY-CoV555 in this patient
population.
In addition, we found no between-group differences with respect to the primary outcome of
sustained recovery or the related outcome of
hospital discharge. An analysis of the association between the day 5 ordinal category and the
time until a sustained recovery suggested a strong
relationship, which supports the use of the day
5 ordinal category for early futility assessment.
The evaluations of clinical status at later time
points (e.g., days 7 and 28) were also consistent
with the status on day 5. These results support
our approach of early evaluation of futility using
data at day 5 to decide on whether a treatment
should proceed to full enrollment. This initial
trial thus confirms the approach taken in the
TICO platform.
On the basis of these preliminary results with
a median of only 31 days of follow-up, the safety
of LY-CoV555 as compared with placebo remains
uncertain. None of the between-group differences
that were observed in the prespecified safety outcomes met the criteria for statistical significance. A limitation of the trial is our inability to
make definitive statements about the safety of
LY-CoV555 as compared with placebo. Since the
sample size was smaller and the duration of follow-up was shorter than planned, the confidence
intervals around major safety outcomes are wide.
Our results should be interpreted in the context of a preliminary study assessing three doses
of LY-CoV555 (700, 2800, and 7000 mg) in outpatients with Covid-19.3 Although no dose-response effect was noted, patients who received
LY-CoV555 may have had slightly increased viral
clearance from the nasopharynx and may have
had a lower risk of hospitalization. In contrast,
the current trial enrolled inpatients, the majority
of whom had hypoxemia, and tested the effect of

LY-CoV555 on a background of remdesivir and
substantial glucocorticoid therapy.
Other forms of passive immunity have been
only minimally investigated to date, although
randomized trials are ongoing. We note that in
prior experience with neutralizing monoclonal
antibodies for acute infections (e.g., in Ebola virus
disease15), various antibodies differed dramatically in efficacy, and certain antibodies had efficacy even in advanced disease. Rapid and rigorous assessment of potential antiviral therapies
for Covid-19, including the use of additional monoclonal antibodies, remains a high priority.
The TICO platform will proceed with the
evaluation of additional Covid-19 treatments, including the use of new neutralizing monoclonal
antibodies. The clinical benefit from other antibody agents, given either as individual or combination therapies, may differ from that of LY-CoV555
owing to differences in epitope target, bindingsite specificity, affinity, tissue levels, effector
functions, and pharmacokinetic profile.
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